Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $17.3333.

IVA has been the topic of several recent analyst reports. Piper Sandler assumed coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price target on shares of Inventiva in a report on Tuesday, September 30th. HC Wainwright raised their price objective on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Wall Street Zen upgraded Inventiva to a “hold” rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th.

Institutional Trading of Inventiva

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC bought a new position in shares of Inventiva in the third quarter worth about $649,000. NewEdge Advisors LLC purchased a new stake in Inventiva in the 3rd quarter valued at about $116,000. Creative Planning bought a new position in Inventiva in the 2nd quarter worth about $32,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after acquiring an additional 9,212 shares during the period. 19.06% of the stock is currently owned by institutional investors.

Inventiva Stock Performance

Shares of IVA opened at $4.18 on Friday. The business has a fifty day moving average of $4.80 and a 200 day moving average of $4.25. Inventiva has a 52-week low of $2.11 and a 52-week high of $7.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.